具体而言,这些抑制剂包括卡格列净、达格列净和恩格列净,它们最初分别于 2013 年 3 月【US Food and Drug Administration. Highlights of Prescribing Information — Invokana】、2014 年 1 月【US Food and Drug Administration. Highlights...
We assessed the impact of SGLT2 inhibitors on cellular senescence induced by high fat and high glucose. Methods Mouse model of DCM and drug administration Male C57BL/6J mice (6-8weeks old, 22 ± 2 g) were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd. After...
- 《Pharmacotherapy the Journal of Human Pharmacology & Drug Therapy》 被引量: 15发表: 2017年 SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus Background Hyperglycemia is an important pathogenic component in the development of microvascular and ...
[8] FDA Drug Safety Communication. FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. 2018. [9] Geerlings S, Fonseca V, Castro-Diaz D, List J, Parikh S. Genital and urinary tract infections in d...
达格列净(dapagli?ozin)是最早研发并全球第一个 SGLT-2 抑制剂,也是目前临床研究证据最多,在心血管安全性评价较为全面的 SGLT-2 抑制剂。 达格列净已完成的IIb和III期临床研究显示:相比安慰剂,达格列净并不增加主要心血管不良事件(Major adverse cardiovascular events,MACE)发生率[1](见图-1)。而最近对 21...
The effect of SGLT2 inhibitors on drug-naive obese type 2 diabetes mellitus patientsEnzyme therapy for patients with exocrine pancreatic insufficiency has been studied a wide variety of conditions, such as enzyme activity, acid tolerance or mixing with foods, though the concept of "replacement for ...
(Orcid ID : 0000-0003-0100-4073) Article type : Original Article SGLT-2 inhibitors and ketoacidosis: a disproportionality analysis in the World Health Organization’s adverse drug reactions database Short title: SGLT-2 inhibitors and ketoacidosis Abdel Nasser Ado Moumouni a , Perrine Robin a , ...
(SGLT-2) inhibitors present potent nephroprotective properties. In clinical trials in patients with type 2 diabetes mellitus, these agents were shown to reduce albuminuria and proteinuria by 30–50% and the incidence of composite hard renal outcomes by 40–50%. Furthermore, their mechanism of ...
First, the sample size was powered to evaluate only a “class effect” but not a “drug effect”. However, an analysis of a nationwide real-world dataset suggested that the risk of cardiovascular events including HF, MI, stroke, and AF would be comparable between different SGLT2 inhibitors,...
SGLT2 Inhibitors Market News June 2023: the U.S. Food and Drug Administration approved Jardiance (empagliflozin) and Synjardy (empagliflozin and metformin hydrochloride) as additions to diet and exercise to improve blood sugar control in children 10 years and older with type 2 diabetes. These appro...